DASA, a potent Src inhibitor, may specifically disrupt the ECM-receptor interaction pathway, thereby inhibiting tumour cell proliferation and disease progression (Alhalabi et al. 2022; Mazharian et al. 2023; Wichaiyo et al. 2021; Zhang et al. 2024). Here, SRC is linked to neoplasm.